ALT5 Sigma マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Peter Tassiopoulos

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	4.9yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Peter Tassiopoulos (55 yo)

less than a year

在職期間

Mr. Peter Tassiopoulos is Chief Executive Officer of ALT5 Sigma Corporation from August 2024. Mr. Tassiopoulos brings over many years of leadership experience across the healthcare, finance and technology...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Tony Isaac	President	9.5yrs	US$817.71k	1.74% € 509.1k
Virland Johnson	Chief Financial Officer	7.3yrs	US$349.35k	0% € 0
Peter Tassiopoulos	Chief Executive Officer	less than a year	データなし	データなし
Tony Giordano	Chief Scientific Officer	4.9yrs	データなし	データなし
Douglas Flanagan	Chief Formulation Advisor	4.4yrs	データなし	データなし

4.9yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: 5AR1の経営陣は経験豊富であると考えられます ( 4.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Tony Isaac	President	9.5yrs	US$817.71k	1.74% € 509.1k
Richard Butler	Independent Director	9.5yrs	US$30.00k	0.10% € 29.2k
John Cooke	Member of Scientific Advisory Board	4.3yrs	データなし	データなし
Nicholas Goeders	Member of Scientific Advisory Board	3.4yrs	データなし	データなし
Christopher Kevil	Chair of Scientific Advisory Board	4.8yrs	データなし	データなし
Edgar Ross	Member of Scientific Advisory Board	4.3yrs	データなし	データなし
Nael Hajjar	Independent Director	6.3yrs	US$14.40k	データなし
John Bitar	Independent Director	4.8yrs	US$18.00k	0.014% € 4.2k
Ron Pitters	Independent Director	no data	データなし	データなし
Joshua Beckman	Member of Scientific Advisory Board	no data	データなし	データなし

4.8yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: 5AR1の取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

ALT5 Sigma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

Insufficient new directors

JanOne Inc., Annual General Meeting, Oct 09, 2023

Recent updates

New major risk - Revenue and earnings growth

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

ALT5 Sigma Corporation announced delayed 10-Q filing

Insufficient new directors

JanOne Regains Compliance with Nasdaq's Listing Rule 5550(b)(1)

JanOne Inc. (NasdaqCM:JAN) completed the acquisition of Alt 5 Sigma Inc.

JanOne Inc. announced delayed annual 10-K filing

JanOne Regains Compliance with Nasdaq’s Listing Requirements

Investor sentiment improves as stock rises 62%

Investor sentiment improves as stock rises 95%

New minor risk - Profit margin trend

New major risk - Shareholder dilution

JanOne Receives Non-Compliance Notice from the Nasdaq Stock Market

JanOne Inc., Annual General Meeting, Oct 09, 2023

New major risk - Share price stability

New major risk - Earnings quality

Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain

JanOne Inc. announced delayed 10-Q filing

Full year 2022 earnings released: EPS: US$1.14 (vs US$6.35 loss in FY 2021)

JanOne Received A Notice from the NASDAQ Stock Market

Third quarter 2022 earnings released: US$0.66 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

JanOne Inc., Annual General Meeting, Nov 02, 2022

JanOne Inc. (NasdaqCM:JAN) enter into a term sheet to acquire Soin Therapeutics LLC Soin Therapeutics LLC for $30 million.

Second quarter 2022 earnings released: EPS: US$3.39 (vs US$2.07 loss in 2Q 2021)

JanOne Inc. Announces an Improved Formulation of JAN101

JanOne Inc. Announces the Issuance of U.S. Patent Covering A Method of Improving Nerve Function Using Jan101

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.26 in 1Q 2021)

High number of new and inexperienced directors

JanOne Receives Notice from Nasdaq for Not Complying with Listing Rules

Full year 2021 earnings released: US$6.35 loss per share (vs US$4.59 loss in FY 2020)

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new and inexperienced directors

Janone Janone Inc. Revises Its Development Strategy Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate Jan101

Janone Inc. Readies Clinical Supply of Lead Product Candidate Jan101 for Distribution to Phase 2B Trial Sites

JanOne Selects Regulatory Partner for Phase 2B Trial as Investigational Plan Is Prepared for FDA Filing

JanOne Announces Initiation of Phase 2b Peripheral Artery Disease Trial for Lead Product Candidate JAN101

Chief Financial Officer recently sold €181k worth of stock

First quarter 2021 earnings released: EPS US$0.26 (vs US$1.33 loss in 1Q 2020)

Full year 2020 earnings released: US$4.59 loss per share (vs US$6.78 loss in FY 2019)

Virland Johnson entered into a definitive agreement to acquire substantially all assets and certain liabilities of ARCA Recycling, Inc. from JanOne Inc. (NasdaqCM:JAN) for $25 million.

JanOne Inc. has completed a Follow-on Equity Offering in the amount of $5.999994 million.

New 90-day high: €13.80

New 90-day high: €6.15

Third quarter 2020 earnings released: US$0.43 loss per share

JanOne Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

New 90-day high - €5.05

Earnings released

New 90-day high - €3.26

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24